272 related articles for article (PubMed ID: 22932786)
1. BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis.
Tufano RP; Teixeira GV; Bishop J; Carson KA; Xing M
Medicine (Baltimore); 2012 Sep; 91(5):274-286. PubMed ID: 22932786
[TBL] [Abstract][Full Text] [Related]
2. BRAF V600E Mutation Lacks Association with Poorer Clinical Prognosis in Papillary Thyroid Carcinoma.
Lai HF; Hang JF; Kuo PC; Kuo CS; Yao SF; Chen JY; Lee CH
Ann Surg Oncol; 2024 May; 31(5):3495-3501. PubMed ID: 38300401
[TBL] [Abstract][Full Text] [Related]
3. BRAF V600E Mutation-Assisted Risk Stratification of Solitary Intrathyroidal Papillary Thyroid Cancer for Precision Treatment.
Huang Y; Qu S; Zhu G; Wang F; Liu R; Shen X; Viola D; Elisei R; Puxeddu E; Fugazzola L; Colombo C; Jarzab B; Czarniecka A; Lam AK; Mian C; Vianello F; Yip L; Riesco-Eizaguirre G; Santisteban P; O'Neill CJ; Sywak MS; Clifton-Bligh R; Bendlova B; Sýkorová V; Xing M
J Natl Cancer Inst; 2018 Apr; 110(4):362-370. PubMed ID: 29165667
[TBL] [Abstract][Full Text] [Related]
4. Association of MicroRNA Expression and BRAF
Pamedytyte D; Simanaviciene V; Dauksiene D; Leipute E; Zvirbliene A; Sarauskas V; Dauksa A; Verkauskiene R; Zilaitiene B
Biomolecules; 2020 Apr; 10(4):. PubMed ID: 32316638
[TBL] [Abstract][Full Text] [Related]
5. Effect and Interactions of BRAF on Lymph Node Metastasis in Papillary Thyroid Carcinoma With Hashimoto Thyroiditis.
Li P; Liu Y; Wei T; Wang X; Zhu J; Yang R; Gong Y; Zhao W
J Clin Endocrinol Metab; 2024 Mar; 109(4):944-954. PubMed ID: 37967234
[TBL] [Abstract][Full Text] [Related]
6. The Coexistence of Genetic Mutations in Thyroid Carcinoma Predicts Histopathological Factors Associated With a Poor Prognosis: A Systematic Review and Network Meta-Analysis.
Zhao L; Wang L; Jia X; Hu X; Pang P; Zhao S; Wang Y; Wang J; Zhang Y; Lyu Z
Front Oncol; 2020; 10():540238. PubMed ID: 33240806
[TBL] [Abstract][Full Text] [Related]
7. Gene mutations as predictors of central lymph mode metastasis in cN0 PTC: A meta-analysis.
Ji J; Shi X
Clin Genet; 2024 Feb; 105(2):130-139. PubMed ID: 37985961
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of minimal extrathyroidal extension in papillary thyroid carcinoma.
Yin DT; Yu K; Lu RQ; Li X; Xu J; Lei M
Medicine (Baltimore); 2016 Dec; 95(52):e5794. PubMed ID: 28033304
[TBL] [Abstract][Full Text] [Related]
9. Progress in long non-coding RNAs as prognostic factors of papillary thyroid carcinoma.
Zhu HN; Song DL; Zhang SN; Zheng ZJ; Chen XY; Jin X
Pathol Res Pract; 2024 Apr; 256():155230. PubMed ID: 38461693
[TBL] [Abstract][Full Text] [Related]
10. Integrated bioinformatics analysis reveals that the expression of cathepsin S is associated with lymph node metastasis and poor prognosis in papillary thyroid cancer.
Tan J; Qian X; Song B; An X; Cai T; Zuo Z; Ding D; Lu Y; Li H
Oncol Rep; 2018 Jul; 40(1):111-122. PubMed ID: 29749483
[TBL] [Abstract][Full Text] [Related]
11. Association of
Blazekovic I; Samija I; Perisa J; Gall Troselj K; Regovic Dzombeta T; Radulovic P; Romic M; Granic R; Sisko Markos I; Frobe A; Kusic Z; Jukic T
Biomedicines; 2024 Feb; 12(3):. PubMed ID: 38540091
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Significance of KIF-12 Functioning as a Tumour Suppressor in Papillary Thyroid Carcinoma.
Gao L; Liu R; Xia Y; Pan A; Shi X; Ma L; Ji J; Hu Y; Li X; An Y; Luo N; Liang Z; Zhou L; Jiang Y
J Cancer; 2024; 15(8):2206-2213. PubMed ID: 38495495
[No Abstract] [Full Text] [Related]
13. Integrated proteogenomic and metabolomic characterization of papillary thyroid cancer with different recurrence risks.
Qu N; Chen D; Ma B; Zhang L; Wang Q; Wang Y; Wang H; Ni Z; Wang W; Liao T; Xiang J; Wang Y; Jin S; Xue D; Wu W; Wang Y; Ji Q; He H; Piao HL; Shi R
Nat Commun; 2024 Apr; 15(1):3175. PubMed ID: 38609408
[TBL] [Abstract][Full Text] [Related]
14. PLK4 reflects extrathyroidal invasion, high tumor stage and poor prognosis in papillary thyroid carcinoma patients.
Hu X; Yu J; Chen M; Pang R
Biomark Med; 2024 Mar; 18(5):169-179. PubMed ID: 38440866
[No Abstract] [Full Text] [Related]
15. Nuclear interaction of Arp2/3 complex and BRAF
Zerfaoui M; Tsumagari K; Toraih E; Errami Y; Ruiz E; Elaasar MSM; Krzysztof M; Sholl AB; Magdeldin S; Soudy M; Abd Elmageed ZY; Boulares AH; Kandil E
Am J Cancer Res; 2022; 12(7):3014-3033. PubMed ID: 35968344
[TBL] [Abstract][Full Text] [Related]
16. Preoperative Factors Associated with Extrathyroidal Extension in Papillary Thyroid Cancer.
Kuo CY; Yang PS; Chien MN; Cheng SP
Eur Thyroid J; 2020 Sep; 9(5):256-262. PubMed ID: 33088794
[TBL] [Abstract][Full Text] [Related]
17. Analysis of Body Mass Index and Clinicopathological Factors in Patients with Papillary Thyroid Carcinoma.
Yan W; Luo X; Gao QJ; Chen BF; Ye H
Diabetes Metab Syndr Obes; 2024; 17():2013-2019. PubMed ID: 38765470
[TBL] [Abstract][Full Text] [Related]
18. BRAF mutation in papillary thyroid carcinoma (PTC) and its association with clinicopathological features and systemic inflammation response index (SIRI).
Xie H; Wei B; Shen H; Gao Y; Wang L; Liu H
Am J Transl Res; 2018; 10(8):2726-2736. PubMed ID: 30210710
[TBL] [Abstract][Full Text] [Related]
19. Interplay of metabolic dysfunction-associated fatty liver disease and papillary thyroid carcinoma: insights from a Chinese cohort.
Xiao R; Wang Q; Ni C; Pan W; Wu W; Cai Y; Xie K; You J
J Endocrinol Invest; 2024 May; ():. PubMed ID: 38787506
[TBL] [Abstract][Full Text] [Related]
20. Occupational daily walking steps have inverse relationship with papillary thyroid cancer risk and progression: a retrospective analysis.
Zhang C; Zhang L; Su Y; Xiang L; Zhang Q; Zhang C; Huan Q
Int J Occup Med Environ Health; 2024 Mar; 37(1):58-71. PubMed ID: 38406822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
